Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. Consolidated revenue for 2008 was EUR689.6 million, operating income was EUR144.7 million and net income was EUR100.4 million.
For more information about Recordati please visit http://www.recordati.com
For further information please contact: Bob Ireland, bireland@kowa.co.uk, Office Tel: +44(0)118-944-3804, Mobile: +44(0)7796-952845
